Morgan Stanley raised the firm’s price target on Phibro Animal Health (PAHC) to $34 from $26 and keeps an Equal Weight rating on the shares. The firm said it is encouraged by the latest beat, and the company’s initial FY26 guidance is strong, pointing to a notably better profit profile into next year as it successfully integrates ZTS MFA business and compelling Phibro Forward initiatives. The shares should rise following the report, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PAHC:
- Phibro Animal Health: Strong Q4 Performance Overshadowed by Growth and Profitability Challenges
- Phibro Animal Health sees FY26 EPS $2.52-$2.70, consensus $2.32
- Phibro Animal Health reports Q4 EPS 57c, consensus 52c
- PAHC Upcoming Earnings Report: What to Expect?
- Phibro Animal Health Declares Quarterly Cash Dividend